Aktienanalyse zu Celcuity Inc. (CELC)CELCCelcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Currently, Celcuity Inc is not a strong buy due to its high volatility and negative earnings, despite the recent FDA approval of its drug Revtorpyk. The stock is trading at $67.94, down 32.43% year-to-date, and has an RSI of 27.85, indicating it is oversold. The main risk is the company's significant net losses, which reached -$78,864,000 in Q2 2026, suggesting ongoing financial instability.

1 analysts cover CELC: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 106.50.